Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial

被引：0

作者：

Stintzing, Sebastian

Tabernero, Josep

Satoh, Taroh

Dasari, Arvind

Lonardi, Sara

Eng, Cathy

Garcia-Carbonero, Rocio

Elez, Elena

Yoshino, Takayuki

Sobrero, Alberto F.

Yao, James C.

Kasper, Stefan

Arnold, Dirk

Basic, Edin

Granold, Matthias

Petschulies, Marco

Wu, Liwen

Chen, Lucy F.

Yang, Zhao

Van Cutsem, Eric

机构：

[1] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany

[2] Vall dHebron Inst Oncol, Vall dHebron Hosp Campus, Barcelona, Spain

[3] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka, Japan

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[5] Veneto Inst Oncol IOV IRCCS Padua, Med Oncol Unit 1, Padua, Italy

[6] Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol, Dept Med, Nashville, TN USA

[7] UCM, Hosp Univ 12 Octubre, Dept Oncol, Imas 12, Madrid, Spain

[8] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[9] Azienda Osped San Martino, Dept Med Oncol, Genoa, Italy

[10] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[11] Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany

[12] Asklepios Tumorzentrum Hamburg, Dept Hematol & Oncol, AK Altona, Hamburg, Germany

[13] Takeda Pharma Vertrieb GmbH & Co KG, Berlin, Germany

[14] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[15] HUTCHMED Int Inc, Florham Pk, NJ USA

[16] Univ Hosp Gasthuisberg, Gastroenterol Digest Oncol, Leuven, Belgium

[17] KULeuven, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e15554

引用

页数：1

共 50 条

[21] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
Grothey, Axel
Sobrero, Alberto F.
Siena, Salvatore
Falcone, Alfredo
Ychou, Marc
Lenz, Heinz-Josef
Yoshino, Takayuki
Cihon, Frank
Wagner, Andrea
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[22] Final results from a phase III trial evaluating panitumumab (pmab) plus best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
Kim, Tae Won
Elme, Anneli
Kusic, Zvonko
Park, Joon Oh
Udrea, Anghel Adrian
Kim, Sun Young
Ahn, Joong Bae
Valencia, Ricardo Villalobos
Srinivasan, Krishnan
Bilic, Ante
Manojlovic, Nebojsa
Dong, Jun
Guan, Xuesong
Lofton-Day, Catherine
Jung, A. Scott
Vrdoljak, Eduard
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer - Response
Gelber, RD
Goldhirsch, A
Cole, BF
Krook, JE
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22): : 1686 - 1686
[24] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
Kuboki, Y.
Yoshino, T.
Yamazaki, K.
Nishina, T.
Komatsu, Y.
Baba, H.
Tsuji, A.
Yamaguchi, K.
Muro, K.
Ohtsu, A.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
[25] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC).
Lee, Chung-Han
Wan, Yin
Smith, Alan D.
Xie, Ran
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study
Lenz, Heinz-Josef
Tabernero, Josep
Yoshino, Takayuki
Lonardi, Sara
Falcone, Alfredo
Miron, Maria Luisa Limon
Saunders, Mark P.
Sobrero, Alberto F.
Park, Young Suk
Monteagudo, Reyes Ferreiro
Hong, Yong Sang
Tomasek, Jiri
Taniguchi, Hiroya
Ciardiello, Fortunato
Sassi, Mouna
Peil, Barbara
Hastedt, Claudia
Studeny, Matus
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[27] COST-EFFECTIVENESS OF PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH BSC ALONE IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS TUMOR STATUS IN THE NETHERLANDS
Graham, C. N.
Borker, R.
Oppe, M.
Groot, C. A. Uyl-de
Barber, B.
Brogan, A. J.
Amado, R. G.
Peeters, M.
Devercelli, G.
ANNALS OF ONCOLOGY, 2008, 19 : 134 - 134
[28] Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
McDermott, David F.
Shah, Ruchit
Gupte-Singh, Komal
Sabater, Javier
Luo, Linlin
Botteman, Marc
Rao, Sumati
Regan, Meredith M.
Atkins, Michael
QUALITY OF LIFE RESEARCH, 2019, 28 (01) : 109 - 119
[29] Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
David F. McDermott
Ruchit Shah
Komal Gupte-Singh
Javier Sabater
Linlin Luo
Marc Botteman
Sumati Rao
Meredith M. Regan
Michael Atkins
Quality of Life Research, 2019, 28 : 109 - 119
[30] Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
Loree, Jonathan M.
Topham, James T.
Kennecke, Hagen Fritz
Feilotter, Harriet
Lee, Young S.
Virk, Shakeel
Kopetz, Scott
Duose, Dzifa Yawa
Manyam, Ganiraju C.
Morris, Jeffrey S.
Maru, Dipen M.
Renouf, Daniel
Jonker, Derek J.
Tu, Dongsheng
O'Callaghan, Christopher J.
Chen, Eric Xueyu
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →